Literature DB >> 26335918

Obliterative Bronchiolitis.

Patrick R Aguilar1, Andrew P Michelson, Warren Isakow.   

Abstract

Obliterative bronchiolitis (OB) is a clinical syndrome marked by progressive dyspnea and cough with the absence of parenchymal lung disease on radiographic studies. Pulmonary function testing reveals an obstructive ventilatory defect that is typically not reversed by inhaled bronchodilator. Transbronchial biopsies are insufficiently sensitive to achieve diagnosis, and in most cases, clinical, physiological, and radiological data obviate the need for the increased risk associated with open lung biopsy. This diagnosis has been documented in a variety of exposures, including fumes from flavoring plants, smoke from burn pits, and environmental sulfur gas. Among lung transplant recipients, "bronchiolitis obliterans syndrome," a disorder with clinical and histopathological similarity to OB, represents the leading cause of long-term allograft dysfunction and mortality. After hematopoietic stem cell transplantation, chronic graft versus host disease of the lung manifests most frequently with similar clinical and pathological features. In all circumstances, immunologic and nonimmunologic mechanisms are thought to lead to airway epithelial dysfunction, which results in progressive airflow obstruction and debility. Augmentation of immunosuppression is occasionally effective in slowing or reversing the progression of disease though a significant number of patients will be nonresponders. Other immunomodulatory methods have been attempted in each circumstance where this pathology has been identified. Unfortunately, OB is poorly understood and often results in sufficient progression of disease to warrant evaluation for lung transplantation (or retransplantation). Here, we review what is known regarding pathophysiology and discuss clinical, pathological, radiological, and therapeutic factors associated with the spectrum of OB-related disease with a particular focus on lung transplantation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26335918     DOI: 10.1097/TP.0000000000000892

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Defining chronic rejection in vascularized composite allotransplantation-The American Society of Reconstructive Transplantation and International Society of Vascularized Composite Allotransplantation chronic rejection working group: 2018 American Society of Reconstructive Transplantation meeting report and white paper Research goals in defining chronic rejection in vascularized composite allotransplantation.

Authors:  Christina L Kaufman; Jean Kanitakis; Annemarie Weissenbacher; Gerald Brandacher; Mandeep R Mehra; Hatem Amer; Bettina G Zelger; Bernhard Zelger; Bohdan Pomahac; Sue McDiarmid; Linda Cendales; Emmanuel Morelon
Journal:  SAGE Open Med       Date:  2020-07-14

Review 2.  Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Hemang Yadav; Steve G Peters; Karina A Keogh; William J Hogan; Patricia J Erwin; Colin P West; Cassie C Kennedy
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-26       Impact factor: 5.742

3.  HMGB1 exacerbates bronchiolitis obliterans syndrome via RAGE/NF-κB/HPSE signaling to enhance latent TGF-β release from ECM.

Authors:  Long He; Fei Sun; Yi Wang; Jianghui Zhu; Jing Fang; Shu Zhang; Qilin Yu; Quan Gong; Boxue Ren; Xudong Xiang; Zhishui Chen; Qin Ning; Jifa Hu; Ping Yang; Cong-Yi Wang
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

4.  A case of imatinib-related obstructive bronchiolitis followed long term.

Authors:  Chika Yajima; Nariaki Kokuho; Kazutoshi Toriyama; Junichiro Kawagoe; Yuki Togashi; Jun Matsubayashi; Hideaki Nakayama; Yasuhiro Setoguchi; Shinji Abe
Journal:  Respir Med Case Rep       Date:  2020-04-04

5.  The importance of central airway dilatation in patients with bronchiolitis obliterans.

Authors:  Mariko Kogo; Hisako Matsumoto; Naoya Tanabe; Toyofumi F Chen-Yoshikawa; Naoki Nakajima; Akihiko Yoshizawa; Tsuyoshi Oguma; Susumu Sato; Natsuko Nomura; Chie Morimoto; Hironobu Sunadome; Shimpei Gotoh; Akihiro Ohsumi; Hiroshi Date; Toyohiro Hirai
Journal:  ERJ Open Res       Date:  2021-10-25

6.  Risk Factors for Post-infectious Bronchiolitis Obliterans in Children: A Systematic Review and Meta-Analysis.

Authors:  Die Liu; Jing Liu; Lipeng Zhang; Yuanmei Chen; Qi Zhang
Journal:  Front Pediatr       Date:  2022-06-09       Impact factor: 3.569

7.  Association Between Promoter Polymorphisms in CD46 and CD59 in Kidney Donors and Transplant Outcome.

Authors:  Laura A Michielsen; Arjan D van Zuilen; Tineke Kardol-Hoefnagel; Marianne C Verhaar; Henny G Otten
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

8.  Interleukin-18: A Novel Participant in the Occurrence, Development, and Drug Therapy of Obliterative Bronchiolitis Postlung Transplantation.

Authors:  Ping Shu; Wei Zhang; Yanfei Zhang; Yanfeng Zhao; Yuping Li; Xiaoqing Zhang
Journal:  Dis Markers       Date:  2021-07-27       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.